Reference : Cabergoline and the risk of valvular lesions in endocrine disease.
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti, Patrizio [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
Livadariu, E. [ > > ]
Markov, M. [ > > ]
Daly, Adrian [Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie >]
Burlacu, M. C. [> > > >]
Betea, Daniela [Centre Hospitalier Universitaire de Liège - CHU > > Endocrinologie clinique >]
Pierard, Luc [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
Beckers, Albert mailto [Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie >]
European Journal of Endocrinology
BioScientifica Ltd
Yes (verified by ORBi)
United Kingdom
[en] Adult ; Aged ; Cross-Sectional Studies ; Dopamine Agonists/adverse effects/therapeutic use ; Echocardiography ; Endocrine System Diseases/drug therapy ; Ergolines/adverse effects/therapeutic use ; Female ; Heart Valve Diseases/chemically induced/pathology ; Humans ; Male ; Middle Aged ; Mitral Valve/drug effects/pathology ; Mitral Valve Insufficiency/chemically induced/pathology ; Risk Factors
[en] AIMS: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown. METHODS AND RESULTS: We performed a cross-sectional, case-control echocardiographic study to assess the valvular status in 102 subjects receiving cabergoline for endocrine disorders and 51 matched control subjects. Cabergoline treatment ranged from 12 to 228 months, with a cumulative dose of 18-1718 mg. Valvular regurgitation was equally prevalent in both groups and was almost exclusively mild. Two cabergoline-treated subjects had moderate mitral regurgitation; there was no relationship between cabergoline dose and the presence or severity of mitral valve regurgitation (P=NS). Mitral valve tenting area was significantly greater in the cabergoline group when compared with the control subjects (P=0.03). Mitral valve leaflet thickening was observed in 5.9% of cabergoline-treated subjects; no relationship with the cumulative cabergoline dose was found. No patient had aortic or tricuspid valvular restriction. CONCLUSION: No significantly increased risk of clinically relevant cardiac valve disorders was found in subjects treated with long-term cabergoline therapy at the doses used in endocrine practice. While exposure to cabergoline appears to be safe during low-dose long-term therapy, an association with subclinical changes in mitral valve geometry cannot be completely excluded.
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Open access
1.pdfNo commentaryPublisher postprint98.12 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.